{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T16:05:01Z","timestamp":1761408301013,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Brazilian Journal of Infectious Diseases"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.bjid.2023.102757","type":"journal-article","created":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T23:08:42Z","timestamp":1676848122000},"page":"102757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0254-4154","authenticated-orcid":false,"given":"Elaine Monteiro","family":"Matsuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0334-0572","authenticated-orcid":false,"given":"Ivana Barros","family":"Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2202-0443","authenticated-orcid":false,"given":"Isabela Penteriche","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5901-2095","authenticated-orcid":false,"given":"Daniela Rodrigues","family":"Colpas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4564-3208","authenticated-orcid":false,"given":"Giselle Ibete Silva","family":"L\u00f3pez-Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3948-743X","authenticated-orcid":false,"given":"Victor Oliveira","family":"Chiavegato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1022-7837","authenticated-orcid":false,"given":"Lu\u00eds Fernando de Macedo","family":"Br\u00edgido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjid.2023.102757_bib0001","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","article-title":"Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies","volume":"4","author":"Trickey","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.bjid.2023.102757_bib0002","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1310\/D0WD-ARAU-U1EF-30MM","article-title":"Tenofovir-containing nucleoside\/nucleotide-only antiretroviral maintenance therapy: decision making and virological outcome","volume":"7","author":"Buehlmann","year":"2006","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.bjid.2023.102757_bib0003","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1468-1293.2009.00752.x","article-title":"MONARK Study Group. Long-term (96-week) follow-up of antiretroviral-na\u00efve HIV-infected patients treated with first-line lopinavir\/ritonavir monotherapy in the MONARK trial","volume":"11","author":"Ghosn","year":"2010","journal-title":"HIV Med"},{"key":"10.1016\/j.bjid.2023.102757_bib0004","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1473-3099(14)70736-4","volume":"14","author":"Cahn","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bjid.2023.102757_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(15)00097-3","article-title":"Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial","volume":"15","author":"Perez-Molina","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bjid.2023.102757_bib0006","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/23744235.2017.1410285","article-title":"Simplification to dual-therapy containing lamivudine and darunavir\/ritonavir or atazanavir\/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy","volume":"50","author":"Calza","year":"2018","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.bjid.2023.102757_bib0007","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1093\/jac\/dkaa319","article-title":"Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy","volume":"75","author":"Calza","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2023.102757_bib0008","doi-asserted-by":"crossref","first-page":"133","DOI":"10.24875\/AIDSRev.20000103","article-title":"Efficacy and safety of triple versus dolutegravir-based dual therapy in patients with HIV-1 infection: a meta-analysis of randomized controlled trials","volume":"23","author":"Shu","year":"2021","journal-title":"AIDS Rev"},{"key":"10.1016\/j.bjid.2023.102757_bib0009","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1089\/aid.2016.0291","article-title":"Dual raltegravir-etravirine combination as maintenance regimen in virologically suppressed HIV-1-infected patients","volume":"33","author":"Calza","year":"2017","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.bjid.2023.102757_bib0010","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.bjid.2023.102757_bib0011","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S2352-3018(21)00100-4","article-title":"Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial","volume":"8","author":"Rojas","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.bjid.2023.102757_bib0012","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s40121-021-00522-7","article-title":"HIV treatment with the two-drug regimen dolutegravir plus lamivudine in real-world clinical practice: a systematic literature review","volume":"10","author":"Patel","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.bjid.2023.102757_bib0015","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","volume":"71","author":"van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bjid.2023.102757_bib0016","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0000000000002275","article-title":"Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials","volume":"83","author":"Cahn","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.bjid.2023.102757_bib0013","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1053\/j.ajkd.2012.08.019","article-title":"A decade after the KDOQI CKD guidelines","volume":"60","author":"Levey","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.bjid.2023.102757_bib0014","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/aid.2019.0171","article-title":"Perspectives on the barrier to resistance for dolutegravir + lamivudine, a two-drug antiretroviral therapy for HIV-1 infection","volume":"36","author":"Boffito","year":"2020","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.bjid.2023.102757_bib0017","doi-asserted-by":"crossref","first-page":"37","DOI":"10.11606\/s1518-8787.2022056004314","article-title":"Impact of COVID-19 on people living with HIV-1: care and prevention indicators at a local and nationwide level, Santo Andr\u00e9, Brazil","volume":"56","author":"Matsuda","year":"2022","journal-title":"Rev Saude Publica"},{"key":"10.1016\/j.bjid.2023.102757_bib0018","unstructured":"Coordena\u00e7\u00e3o-Geral de Vigil\u00e2ncia do HIV\/AIDS e das Hepatites Virais \u2013 CGAHV. Nota informativa N 22\/2021-CGAHV\/.DCCI\/SVS\/MS, 2020. Minist\u00e9rio da Sa\u00fade, Brasil.http:\/\/azt.aids.gov.br\/documentos\/siclom_operacional\/Nota%20Informativa%20 N% C2%BA%2022_2021-CGAHV_DCCI_SVS_MS.pdf."},{"key":"10.1016\/j.bjid.2023.102757_bib0019","unstructured":"European AIDS Clinical Society (EACS). Switch strategies - switch strategies for virologically suppressed persons. EACS Guidelines 2021. https:\/\/eacs.sanfordguide.com\/art\/switch-strategies."},{"key":"10.1016\/j.bjid.2023.102757_bib0020","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/jac\/dkaa479","article-title":"Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: week 96 results of ART-PRO pilot study","volume":"76","author":"Rial-Crestelo","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2023.102757_bib0021","series-title":"Abstracts of the 9th International AIDS Society Conference on HIV Science, Paris, France","article-title":"Dual regimen with dolutegravir and lamivudine maintains virologic suppression even in heavily treatment experienced HIV-infected patients: 96 weeks results from maintenance DOLULAM study","author":"Reynes","year":"2017"},{"key":"10.1016\/j.bjid.2023.102757_bib0022","doi-asserted-by":"crossref","first-page":"ofy113","DOI":"10.1093\/ofid\/ofy113","article-title":"Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: a cohort study","volume":"5","author":"Gagliardini","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.bjid.2023.102757_bib0023","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/hiv.12781","article-title":"Dual therapy with renally adjusted lamivudine and dolutegravir: a switch strategy to manage comorbidity and toxicity in older, suppressed patients?","volume":"20","author":"Tan","year":"2019","journal-title":"HIV Med"},{"key":"10.1016\/j.bjid.2023.102757_bib0024","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/QAD.0000000000002871","article-title":"To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment","volume":"35","author":"Mounzer","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.bjid.2023.102757_bib0025","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/QCO.0000000000000453","article-title":"Dolutegravir resistance mutations: lessons from monotherapy studies","volume":"31","author":"Blanco","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.bjid.2023.102757_bib0026","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1177\/0192623313503519","article-title":"HIV treatment and associated mitochondrial pathology: review of 25 years of in vitro, animal, and human studies","volume":"42","author":"Gardner","year":"2014","journal-title":"Toxicol Pathol"}],"container-title":["The Brazilian Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S141386702300017X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S141386702300017X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T16:00:06Z","timestamp":1761408006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S141386702300017X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S141386702300017X"],"URL":"https:\/\/doi.org\/10.1016\/j.bjid.2023.102757","relation":{},"ISSN":["1413-8670"],"issn-type":[{"type":"print","value":"1413-8670"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction","name":"articletitle","label":"Article Title"},{"value":"The Brazilian Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjid.2023.102757","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedade Brasileira de Infectologia.","name":"copyright","label":"Copyright"}],"article-number":"102757"}}